Raymond James Financial Services Advisors Inc. purchased a new stake in Evolus Inc (NASDAQ:EOLS) in the second quarter, Holdings Channel reports. The fund purchased 10,808 shares of the company’s stock, valued at approximately $303,000.
A number of other hedge funds also recently bought and sold shares of the stock. Bank of Montreal Can acquired a new position in shares of Evolus during the second quarter worth $512,000. Citadel Advisors LLC acquired a new position in shares of Evolus during the first quarter worth $1,554,000. Landscape Capital Management L.L.C. acquired a new position in shares of Evolus during the first quarter worth $639,000. California Public Employees Retirement System acquired a new position in shares of Evolus during the first quarter worth $293,000. Finally, BlackRock Inc. acquired a new position in shares of Evolus during the first quarter worth $1,710,000. 13.20% of the stock is owned by institutional investors and hedge funds.
NASDAQ EOLS opened at $26.07 on Wednesday. Evolus Inc has a 1 year low of $6.75 and a 1 year high of $39.50.
Evolus (NASDAQ:EOLS) last released its quarterly earnings data on Thursday, August 2nd. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.05). research analysts expect that Evolus Inc will post -1.9 EPS for the current fiscal year.
In related news, Director Kristine Romine acquired 2,200 shares of the firm’s stock in a transaction on Friday, June 8th. The stock was bought at an average price of $28.54 per share, for a total transaction of $62,788.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Corp Alphaeon sold 1,000,000 shares of the company’s stock in a transaction on Monday, July 23rd. The shares were sold at an average price of $18.80, for a total transaction of $18,800,000.00. The disclosure for this sale can be found here. Insiders acquired 20,800 shares of company stock valued at $509,456 in the last 90 days.
A number of brokerages recently commented on EOLS. JMP Securities boosted their target price on shares of Evolus from $22.00 to $30.00 and gave the stock an “outperform” rating in a research note on Tuesday, May 29th. ValuEngine upgraded shares of Evolus from a “hold” rating to a “buy” rating in a research note on Monday, July 2nd. Cantor Fitzgerald set a $35.00 price objective on shares of Evolus and gave the company a “buy” rating in a research note on Monday, July 23rd. Zacks Investment Research downgraded shares of Evolus from a “buy” rating to a “hold” rating in a research note on Thursday, August 2nd. Finally, Mizuho upped their price objective on shares of Evolus from $16.00 to $33.00 and gave the company a “buy” rating in a research note on Monday, June 11th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $30.40.
Evolus, Inc provides medical aesthetic products for physicians and their patients in the United States. It offers DWP-450, an injectable 900 kilodalton botulinum toxin type A complex designed to address the needs of the facial aesthetics market. The company was founded in 2012 and is headquartered in Irvine, California.
Read More: Find a Trading Strategy That Works
Want to see what other hedge funds are holding EOLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Evolus Inc (NASDAQ:EOLS).
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.